{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:55:43Z","timestamp":1761587743096,"version":"build-2065373602"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T00:00:00Z","timestamp":1663891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008368","name":"Gigtforeningen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008733","name":"H\u00f8rslev-Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008733","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010727","name":"Axel Muusfeldts Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010727","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014561","name":"Bristol-Myers Squibb Co Research & Development Seattle","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014561","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006576","name":"Civilingeni\u00f8r Frode V. Nyegaard og Hustrus Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006576","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009898","name":"Beckett-Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009898","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.intimp.2022.109267","type":"journal-article","created":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T20:48:50Z","timestamp":1664311730000},"page":"109267","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["MAPK activated kinase 2 inhibition shifts the chemokine signature in arthritis synovial fluid mononuclear cells from CXCR3 to CXCR2"],"prefix":"10.1016","volume":"112","author":[{"given":"Tue W.","family":"Kragstrup","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne Sofie","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mads","family":"Br\u00fcner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00f8ren","family":"Lomholt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morten A","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Schafer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bent","family":"Deleuran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.intimp.2022.109267_b0005","doi-asserted-by":"crossref","first-page":"102731","DOI":"10.1016\/j.autrev.2020.102731","article-title":"Spondylitis-psoriasis-enthesitis-enterocolitis-dactylitis-uveitis-peripheral synovitis (SPEED-UP) treatment","volume":"20","author":"Br\u00fcner","year":"2021","journal-title":"Autoimmun. Rev."},{"issue":"1","key":"10.1016\/j.intimp.2022.109267_b0010","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2018.1","article-title":"Rheumatoid arthritis","volume":"4","author":"Smolen","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"1","key":"10.1016\/j.intimp.2022.109267_b0015","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-020-02349-y","article-title":"T helper cells in synovial fluid of patients with rheumatoid arthritis primarily have a Th1 and a CXCR3(+)Th2 phenotype","volume":"22","author":"Aldridge","year":"2020","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.intimp.2022.109267_b0020","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1002\/art.27470","article-title":"Deficiency of CXCR2, but not other chemokine receptors, attenuates autoantibody-mediated arthritis in a murine model","volume":"62","author":"Jacobs","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2022.109267_b0025","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3389\/fimmu.2012.00263","article-title":"CXCR2: From Bench to Bedside","volume":"3","author":"Stadtmann","year":"2012","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2022.109267_b0030","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1006\/clim.2000.4957","article-title":"CXCR3 and CCR5 ligands in rheumatoid arthritis synovium","volume":"98","author":"Patel","year":"2001","journal-title":"Clin. Immunol. (Orlando, Fla.)"},{"key":"10.1016\/j.intimp.2022.109267_b0035","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ctrv.2017.11.007","article-title":"CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation - A target for novel cancer therapy","volume":"63","author":"Tokunaga","year":"2018","journal-title":"Cancer Treat. Rev."},{"issue":"3","key":"10.1016\/j.intimp.2022.109267_b0040","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1046\/j.1365-2249.2002.01913.x","article-title":"In vivo activated T cells in rheumatoid synovitis. Analysis of Th1- and Th2-type cytokine production at clonal level in different stages of disease","volume":"129","author":"Gerli","year":"2002","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.intimp.2022.109267_b0045","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2174\/1874312901206010209","article-title":"The p38 MAPK Pathway in Rheumatoid Arthritis: A Sideways Look","volume":"6","author":"Clark","year":"2012","journal-title":"Open Rheumatology J."},{"key":"10.1016\/j.intimp.2022.109267_b0050","first-page":"176","article-title":"In vitro target validation and in vivo efficacy of p38 MAP kinase inhibition in established chronic collagen-induced arthritis model: a pre-clinical study","volume":"28","author":"Triantaphyllopoulos","year":"2010","journal-title":"Clin. Exp. Rheumatol."},{"issue":"2","key":"10.1016\/j.intimp.2022.109267_b0055","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/art.24266","article-title":"Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis","volume":"60","author":"Cohen","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2022.109267_b0060","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1002\/art.24485","article-title":"Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies","volume":"60","author":"Damjanov","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2022.109267_b0065","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1177\/0960327117715901","article-title":"Differential effect of p38 and MK2 kinase inhibitors on the inflammatory and toxicity biomarkers in vitro","volume":"37","author":"Singh","year":"2018","journal-title":"Hum. Exp. Toxicol."},{"key":"10.1016\/j.intimp.2022.109267_b0070","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/ard.2007.074278","article-title":"The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis","volume":"67","author":"Schett","year":"2008","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.intimp.2022.109267_b0075","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1084\/jem.20172063","article-title":"Selective inhibition of the p38\u03b1 MAPK-MK2 axis inhibits inflammatory cues including inflammasome priming signals","volume":"215","author":"Wang","year":"2018","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2022.109267_b0080","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00722","article-title":"Targeting MK2 Is a Novel Approach to Interfere in Multiple Myeloma","volume":"9","author":"Guo","year":"2019","journal-title":"Front. Oncol."},{"issue":"7","key":"10.1016\/j.intimp.2022.109267_b0085","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/intbio\/zyz025","article-title":"Substrate-based kinase activity inference identifies MK2 as driver of colitis","volume":"11","author":"Strasser","year":"2019","journal-title":"Integr. Biol. (Camb)"},{"key":"10.1016\/j.intimp.2022.109267_b0090","first-page":"123","article-title":"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the MK2 Inhibitor ATI-450 in Healthy Subjects: A Placebo-Controlled, Randomized Phase 1 Study","volume":"13","author":"Gordon","year":"2021","journal-title":"Clin. Pharmacol."},{"issue":"9","key":"10.1016\/j.intimp.2022.109267_b0095","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.intimp.2022.109267_b0100","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2010.133645","article-title":"The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general","volume":"70","author":"Rudwaleit","year":"2011","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.intimp.2022.109267_b0105","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.intimp.2022.109267_b0110","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-016-0964-7","article-title":"The interleukin-20 receptor axis in early rheumatoid arthritis: novel links between disease-associated autoantibodies and radiographic progression","volume":"18","author":"Kragstrup","year":"2016","journal-title":"Arthritis Res. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2022.109267_b0115","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/acr2.11094","article-title":"Responses to Cytokine Inhibitors Associated with Cellular Composition in Models of Immune-Mediated Inflammatory Arthritis","volume":"2","author":"Nielsen","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.intimp.2022.109267_b0120","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s41927-018-0036-5","article-title":"Resveratrol displays anti-inflammatory properties in an ex vivo model of immune mediated inflammatory arthritis","volume":"2","author":"Lomholt","year":"2018","journal-title":"BMC Rheumatol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109267_b0125","doi-asserted-by":"crossref","DOI":"10.1186\/s12865-021-00471-3","article-title":"Nitro-fatty acids decrease type I interferons and monocyte chemoattractant protein 1 in ex vivo models of inflammatory arthritis","volume":"22","author":"Hansen","year":"2021","journal-title":"BMC Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109267_b0130","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-022-02737-6","article-title":"Tumor necrosis factor alpha neutralization attenuates immune checkpoint inhibitor-induced activation of intermediate monocytes in synovial fluid mononuclear cells from patients with inflammatory arthritis","volume":"24","author":"S\u00f8rensen","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.intimp.2022.109267_b0135","unstructured":"D. Simone, S.H., N. Ansar, A. Davies, K. Doig, P. Bowness, A Mitogen-Associated Protein Kinase (MAPK) Associated Kinase 2 Inhibitor Decreases in Vitro Th17 and Monocyte Inflammatory Responses in Spondyloarthritis. Arthritis Rheumatol 69 (suppl 10) (2017)."},{"key":"10.1016\/j.intimp.2022.109267_b0140","doi-asserted-by":"crossref","unstructured":"T.W. Kragstrup et al. IL-12\/IL-23p40 identified as a downstream target of apremilast in ex vivo models of arthritis. Ther Adv Musculoskelet Dis 11 (2019) 1759720X19828669, doi:10.1177\/1759720X19828669.","DOI":"10.1177\/1759720X19828669"},{"key":"10.1016\/j.intimp.2022.109267_b0145","doi-asserted-by":"crossref","first-page":"8463","DOI":"10.4049\/jimmunol.179.12.8463","article-title":"Blockade of chemokine receptor CXCR3 inhibits T cell recruitment to inflamed joints and decreases the severity of adjuvant arthritis","volume":"179","author":"Mohan","year":"2007","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2022.109267_b0150","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1189\/jlb.1102573","article-title":"Antibody-mediated blockade of the CXCR3 chemokine receptor results in diminished recruitment of T helper 1 cells into sites of inflammation","volume":"73","author":"Xie","year":"2003","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.intimp.2022.109267_b0155","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.4049\/jimmunol.169.5.2685","article-title":"Targeting the function of IFN-gamma-inducible protein 10 suppresses ongoing adjuvant arthritis","volume":"169","author":"Salomon","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2022.109267_b0160","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2018.00271","article-title":"The Role of CXCR3 and Its Chemokine Ligands in Skin Disease and Cancer","volume":"5","author":"Kuo","year":"2018","journal-title":"Front. Med."},{"issue":"1","key":"10.1016\/j.intimp.2022.109267_b0165","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-46791-8","article-title":"Cooperative and distinct functions of MK2 and MK3 in the regulation of the macrophage transcriptional response to lipopolysaccharide","volume":"9","author":"Ehlting","year":"2019","journal-title":"Sci. Rep."},{"issue":"27","key":"10.1016\/j.intimp.2022.109267_b0170","doi-asserted-by":"crossref","first-page":"24113","DOI":"10.1074\/jbc.M111.235275","volume":"286","author":"Ehlting","year":"2011","journal-title":"J. Biological Chem."},{"key":"10.1016\/j.intimp.2022.109267_b0175","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.4049\/jimmunol.177.3.1913","article-title":"MAPKAP kinase 2-deficient mice are resistant to collagen-induced arthritis","volume":"177","author":"Hegen","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2022.109267_b0180","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/blood.V93.7.2173","article-title":"Metalloproteinases are involved in lipopolysaccharide- and tumor necrosis factor-alpha-mediated regulation of CXCR1 and CXCR2 chemokine receptor expression","volume":"93","author":"Khandaker","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2022.109267_b0185","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1365-2567.2005.02133.x","article-title":"Regulation of human neutrophil chemokine receptor expression and function by activation of Toll-like receptors 2 and 4","volume":"115","author":"Sabroe","year":"2005","journal-title":"Immunology"},{"key":"10.1016\/j.intimp.2022.109267_b0190","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41423-020-0412-0","article-title":"Neutrophil chemoattractant receptors in health and disease: double-edged swords","volume":"17","author":"Metzemaekers","year":"2020","journal-title":"Cell. Mol. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2022.109267_b0195","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1038\/sj.bjp.0707462","article-title":"Blockade of the chemokine receptor CXCR2 ameliorates adjuvant-induced arthritis in rats","volume":"153","author":"Barsante","year":"2008","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109267_b0200","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.bbrc.2009.12.025","article-title":"Pharmacological targeting reveals distinct roles for CXCR2\/CXCR1 and CCR2 in a mouse model of arthritis","volume":"391","author":"Min","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.intimp.2022.109267_b0205","doi-asserted-by":"crossref","first-page":"7492","DOI":"10.4049\/jimmunol.162.12.7492","article-title":"The role of an epithelial neutrophil-activating peptide-78-like protein in rat adjuvant-induced arthritis","volume":"162","author":"Halloran","year":"1999","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2022.109267_b0210","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S2213-2600(16)30227-2","article-title":"Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial","volume":"4","author":"O'Byrne","year":"2016","journal-title":"Lancet Respir. Med."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922007512?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922007512?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:50:33Z","timestamp":1761587433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922007512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":42,"alternative-id":["S1567576922007512"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109267","relation":{},"ISSN":["1567-5769"],"issn-type":[{"type":"print","value":"1567-5769"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MAPK activated kinase 2 inhibition shifts the chemokine signature in arthritis synovial fluid mononuclear cells from CXCR3 to CXCR2","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109267","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109267"}}